ImmunoMet Therapeutics

10:30 AM - 10:45 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Our lead molecule, IM156, is an OXPHOS inhibitor with demonstrated impressive in-vivo efficacy in resistant solid tumors. IM156 is currently in Phase 1 with a good safety profile and is expected to progress into Phase 2 in 2020. We have initiated a second program in fibrosis. Immunomet also owns a large library of biguanides with the potential to develop, or partner, new products. The company was founded in 2015, is headquartered in the Houston JLABs near MD Anderson, and has raised $20M to date.
Company Type:
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
IM56
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
ImmunoMet Therapeutics